Quick Answer
LENZ Therapeutics, Inc. reported Stockholders Equity of $284.34 million for fiscal year 2025.
LENZ Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $284.34M | +39.3% |
| 2024 | $204.08M | +320.1% |
| 2023 | -$92.71M | -283.6% |
| 2022 | -$24.17M | -106.3% |
| 2021 | $384.05M | +687.2% |
| 2020 | -$65.41M | -2849.0% |
| 2019 | -$2.22M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $193.93M | -9.9% | -6.0% |
| June 30, 2025 | $206.37M | +7.0% | +7.5% |
| March 31, 2025 | $192.01M | -3.1% | -5.9% |
| December 31, 2024 | $204.08M | +320.1% | -5.2% |
| September 30, 2024 | $215.28M | +409.5% | +11.6% |
| June 30, 2024 | $192.92M | +476.7% | -2.6% |
| March 31, 2024 | $198.17M | +640.3% | +313.7% |
| December 31, 2023 | -$92.71M | -283.6% | -33.3% |
- LENZ Therapeutics, Inc. showed an increase of +39.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, LENZ Therapeutics, Inc.’s stockholders equity has grown by 12919.6% (from -$2.22 million to $284.34 million).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: